9 Results for "

H69

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "H69" in MCE Product Catalog:

Cat. No.: HY-P10137
CAS No.: 1801415-23-5
Synonyms: JR11
Satoreotide (JR11) is a somatostatin receptor subtype 2 (sstr2)-selective antagonist. Satoreotide can be used as a PET imaging agent when labeled with 68Ga. Satoreotide can be used for cancer research .
loading...
    loading...
Cat. No.: HY-118899
CAS No.: 343247-32-5
Purity:  97.39%
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

XR5944 is an anti-tumor compound with DNA-targeting activity. As a topoisomerase inhibitor, XR5944 can effectively inhibit the activities of topoisomerase I and II. XR5944 shows excellent anti-tumor activity against human and mouse tumor cells in vitro and in vivo. XR5944 exhibits significant potency in multiple cell lines, with IC50 values of 0.04-0.4 nM. XR5944 is not affected by atypical drug resistance in cells and remains significantly active even in cells overexpressing P-glycoprotein or multidrug resistance-related proteins. XR5944 showed anti-tumor efficacy in human tumor models of H69 small cell lung cancer and HT29 colon cancer, inducing tumor regression in most animals in the HT29 model. XR5944 can be used to study biological processes related to colon and lung cancer .
loading...
    loading...
Cat. No.: HY-175757
HsClpP activator-2 is an orally active HsClpP agonist with a KD of 40 nM. HsClpP activator-2 potently inhibits SCLC cells including H69 (IC50 = 0.17 μM) and H82 (IC50 = 0.19 μM). HsClpP activator-2 disrupts mitochondrial membrane potential (MMP), as well as induces apoptosis and ROS in H82 cells. HsClpP activator-2 significantly inhibits tumor growth in non-SMC xenograft models with a tumor growth inhibition. HsClpP activator-2 can be used for the study of small cell lung carcinoma (SCLC) .
loading...
    loading...
Cat. No.: HY-19137
CAS No.: 154889-68-6
Synonyms: KW 2189 free base
Target:  

Antibiotic

Research Areas:  

Infection Cancer

Pibrozelesin (KW 2189 free base) is the derivative of antibiotic Duocarmycin B2. Pibrozelesin exhibits antitumor activity, inhibits proliferation of cell H69 with an IC50 of 1.9 μM. Pibrozelesin induces the DNA strand breaks upon activation via carboxyl esterase .
loading...
    loading...
Cat. No.: HY-P11405
CAS No.: 122481-75-8
Target:  

Neurotensin Receptor

Research Areas:  

Neurological Disease Cancer

[D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is a potent inhibitor of cell growth in small cell lung cancer (SCLC). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is also a neuropeptide antagonist, capable of blocking colony formation stimulated by various neuropeptides (including vasopressin and bradykinin). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the mobilization of Ca 2+ and the activation of mitogen-activated protein kinases induced by vasopressin or bradykinin. [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the growth of H-69 xenograft tumors in nude mice .
loading...
    loading...
Cat. No.: HY-159096
Target:  

Apoptosis

Research Areas:  

Cancer

Apoptosis inducer 21 (Compound 5h) inhibits the proliferation of lung cancer cell H69AR with an IC50 of 1.58 μM. Apoptosis inducer 21 arrests the cell cycle at G0/G1 phase, induces apoptosis in H69AR .
loading...
    loading...
Cat. No.: HY-163632
CAS No.: 2758436-98-3
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-112 (SPP10) is an EGFR kinase inhibitor which exhibits IC50s of 2.31 ± 0.3, 3.16 ± 0.8, and 4.2 ± 0.2 μM, against MCF-7, H69AR, and PC-3 cancer cells, respectively. EGFR-IN-112 also demonstrates selective cytotoxicity against cancer cells .
loading...
    loading...
Cat. No.: HY-120436
CAS No.: 113785-48-1
Target:  

Drug Derivative

Research Areas:  

Cancer

RM 49 is the derivative of Mitomycin C (HY-13316). RM 49 exhibits cytotoxicity in SCLC and NSCLC lung cancer cells with IC50 of 0.01-0.5 μg/mL. RM 49 exhibits high relative antitumor activity in compared with Mitomycin C, Cisplatin (HY-17394), Carboplatin (HY-17393) and Doxorubicin (HY-15142) .
loading...
    loading...
Cat. No.: HY-181838
CAS No.: 3064485-73-7
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CIRc-014 is an orally active Cyclin A/B inhibitor with a Cyclin A IC50 of 0.05 μM, Cyclin A Kd of 2.7 nM, Cyclin B IC50 of less than 0.02 μM and Cyclin B Kd of 1.0 nM. CIRc-014 activates the spindle assembly checkpoint and promotes the formation of a complex between Cyclin B and CDK2 by blocking the RxL interaction of Cyclin A/B. CIRc-014 can induce replication stress, DNA damage, mitotic arrest and apoptosis in tumor cells. CIRc-014 showed tumor growth inhibition and regression in NCI-H69 and NCI-H446 small cell lung cancer xenograft models. CIRc-014 can be used for the research of small-cell lung cancer .
loading...
    loading...